Ferrum Health Partners with TaiHao Medical to Advance Women’s Health Through the Use of AI in Breast Ultrasound Diagnosis
2022-08-04 10:00:00 – Sunnyvale, California, United States – (PR Distribution™)
Ferrum Health’s enterprise AI platform continues to grow with the addition of TaiHao Medical’s breast ultrasound decision support used to assist radiologists in the early detection of breast cancer.
Ferrum Health, the industry leader in enterprise AI solutions for global health systems, announces a partnership with TaiHao Medical to bring AI decision support to breast ultrasound exams. The partnership is valuable in early cancer detection, providing radiologists with real-time AI analysis of breast ultrasound images on patients referred for further diagnostic ultrasound examination after a routine mammogram.
The early detection of breast cancer saves lives, and routine mammograms are the first step in the screening process. According to the American Cancer Society, about 10 to 12 percent of women are brought back for additional diagnostic testing after a routine screening mammogram. Ultrasound is often used in follow-up exams to further understand findings from the initial mammogram. AI, in the form of breast ultrasound computer-aided diagnosis decision support, can assist the radiologist in assessing images and identifying cancer.
Breast screening is rapidly evolving, and AI will play a role in the improvement screening exams bring to patient care and outcomes. AI used in the quality workflow as a second read or AI used in the CAD workflow will help address medical errors, in the case of breast screening that’s, missed cancer diagnoses,” said Pelu Tran, CEO and Co-Founder of Ferrum Health. “The goal is AI that keeps people healthy, assesses risk, and gets patients the care they need when they need it.”
The addition of TaiHao Medical’s BU-CAD™ for diagnostic ultrasound exams expands the Ferrum Enterprise AI Platform and provides radiologists with another tool in the fight against cancer. BU-CAD™ supports radiologists and breast surgeons in detecting and diagnosing breast lesions on ultrasound images. In addition, the AI tool provides additional information such as score of lesion characteristics (SLC), BI-RADS category, and BI-RADS descriptors.
“We believe in early detection, early treatment, and the most lives saved. At TaiHao Medical, we design and develop AI medical software to help healthcare providers manage increasing workloads. Our team focuses on breast ultrasound screening for women who are called back for follow-up exams,” said Simon Lai, CEO and co-founder of TaiHao Medical. “We are pleased to work with Ferrum, a leader in AI HUBs for medical care. Together we can raise awareness around the use of AI as a method of quality control as well as a second opinion.”
Ferrum’s enterprise AI platform simplifies healthcare AI, allowing health systems to deploy multiple AI algorithms across all its facilities. Ferrum’s AI platform integrates a vast catalog of validated AI applications in the oncology, orthopedic, trauma, vascular, and neurology clinical space. Ferrum’s population health approach to AI deployment ensures world-class patient safety technology is available for all patients, assisting hospitals in driving equitable care and patient outcomes.
Image Note: Figure 2 above, demonstrates how the software annotated the image by creating a bounding box surrounding the lesion, depicted the lesion contour with dots, and applied output diagnosis results.
About Ferrum Health
Ferrum Health developed an enterprise AI deployment platform to improve patient outcomes by democratizing health systems’ access to the most innovative and impactful clinical AI technologies worldwide. The solution provides end-to-end AI Hubs able to run countless applications across many service lines and seamlessly integrates clinical imaging and administrative data. As of 2022, more than 750,000 unique patient records have been analyzed via the Ferrum AI Hub platform. For more information: www.ferrumhealth.com
About TaiHao Medical, Inc.
TaiHao Medical has received US Federal Food and Drug Administration, Japan Pharmaceuticals and Medical Devices Agency, Taiwan Food and Drug Administration, China National Medical Products Administration clearance and was granted more than ten patents from various countries. Our leading technology and expertise in real-time AI detection of early cancer in 3D Automated Breast Ultrasound (ABUS) & 2D Hand-held Ultrasound (HHUS) images can be painlessly incorporated into the hospital’s existing PACS and RIS system. TaiHao Medical actively participates in government screening programs, collaborates with breast centers, mammography clinics, insurance companies, and ultrasound machine manufacturers to bring a cost and time-saving solution to the public. For more information: www.taihaomed.com